|Bid||51.72 x 1200|
|Ask||51.76 x 1000|
|Day's Range||51.64 - 52.53|
|52 Week Range||27.79 - 57.55|
|PE Ratio (TTM)||38.20|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.89|
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena ...
Short interest is low for GMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The $1.22 billion in inflows that ETFs holding GMED received over the last one-month is a decline from earlier in the period and among the weakest of the past year.
The Audubon, Pennsylvania-based company said it had net income of 44 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
AUDUBON, Pa., Aug. 01, 2018-- Globus Medical, Inc., a leading musculoskeletal solutions company, today announced its financial results for the second quarter ended June 30, 2018.. Worldwide sales were ...
Short interest is low for GMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The $1.18 billion in inflows that ETFs holding GMED received over the last one-month is a decline from earlier in the period and among the weakest of the past year.
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In the first quarter of this year, Zimmer Biomet’s (ZBH) knee device revenue grew ~1.8% YoY (year-over-year) to $713.3 million from $700.8 million. In the Americas, EMEA (Europe, the Middle East, and Africa), and Asia-Pacific, the knee segment generated revenue of $417.2 million, $188.9 million, and $107.2 million, respectively, reflecting a ~2.5% decline, ~12.4% growth, and ~2.3% growth YoY from $428.0 million, $167.9 million, and $104.9 million.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2018 after the market close on Wednesday, August 1, 2018. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, will showcase its advanced technologies at the Scoliosis Research Society’s (SRS) 25th Annual International Meeting on Advanced Spine Techniques (IMAST) being held July 11-14, 2018, in Los Angeles, California. The company will also highlight its robotics platform technology through an industry workshop at IMAST, ExcelsiusGPS® First Clinical Experiences, featuring its revolutionary robotic guidance and navigation system on July 13 from 12:00-1:00 pm led by Dr. Jeffrey A. Goldstein, Chief of Spine Service for Education and Director of the Spine Fellowship at NYU Langone Orthopedic Hospital.
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on NSPR sign up now at www.wallstequities.com/registration. Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Appliances & Equipment stocks: Globus Medical Inc. (NYSE: GMED), InspireMD Inc. (NYSE AMER: NSPR), Lantheus Holdings Inc. (NASDAQ: LNTH), and LivaNova PLC (NASDAQ: LIVN).
“This is an exciting time for Globus Trauma as we continue to execute our product launch strategy and build a comprehensive Trauma product portfolio,” said Barclay Davis, Vice President, Orthopedic Trauma.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, announced today a new clinical milestone with the successful implantation of over 3,000 screws using ExcelsiusGPS®, the company’s revolutionary robotic guidance and navigation system. Since the launch of ExcelsiusGPS® in late 2017, orthopedic and neurosurgeons have used the system with three compatible imaging modalities (preoperative CT, intraoperative CT, and fluoroscopic imaging) across a variety of spine surgery procedures to minimize radiation exposure, streamline workflow, and assist in screw placement. A recent white paper comparing robotic-assisted versus conventional screw placement demonstrates some of the benefits of this technology. “Having completed installations and surgeon training programs through the first half of 2018, we see surgeons using this technology in open and minimally invasive spine procedures including posterior cervical fusion, sacroiliac joint fusion, and thoracolumbar fusion with posterior and single position lateral approaches,” said Chief Executive Officer Dave Demski.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning the link betweenRead More...
Globus Medical (GMED) has missed three consensus revenue estimates and one consensus EPS estimate in the last 20 quarters. It has a dividend yield of 0% compared to the sector and the S&P 500 at 0.9% and 2.3%, respectively. What contributed to GMED’s valuations?
Biotech stocks are also capitalizing on AI’s potential to deliver revolutionary drugs and speed up drug discovery. “I believe that AI is a sleeping giant for healthcare in general,” Eric Horvitz, director of Microsoft Research Labs, said earlier this year.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, today announced the launch of the CREO® Fenestrated Screw System used in the treatment of patients with advanced stage tumors of the thoracolumbar spine. CREO® fenestrated screws, when augmented with the company’s FORTRESS™ radiopaque bone cement, are designed to restore the structural integrity of the spine at vertebral levels affected by metastatic bone disease.
Cantor Fitzgerald is starting coverage on biotech companies in the spinal segment, a market that the investment house thinks has a $9-billion global market opportunity. Globus Medical Inc (NYSE:GMED) earned an “Overweight” rating from Cantor Fitzgerald. GMED stock has a market cap of $5.41 billion and is valued at 10.6 times its book value per share.
WallStEquities.com monitors four Medical Appliances and Equipment stocks, namely: Globus Medical Inc. (NYSE: GMED), Inspire Medical Systems Inc. (NYSE: INSP), InspireMD Inc. (NYSE AMER: NSPR), and LivaNova PLC (NASDAQ: LIVN). Audubon, Pennsylvania headquartered Globus Medical Inc.'s shares recorded a trading volume of 636,640 shares last Friday.
Spine stocks were steadied with supportive coverage from the Street this week. The Ratings Cantor Fitzgerald analysts Craig Bijou and Jordan Abrams initiated coverage on: Globus Medical Inc (NYSE: GMED ...
AUDUBON, Pa., May 21, 2018-- Globus Medical, Inc., a leading musculoskeletal solutions company, today announced the appointment of Daniel Gregoris to Vice President of Sales for the company’ s emerging ...